Quick Answer
Protagenic Therapeutics, Inc.new reported Total Revenue of $0.00 for fiscal year 2016.
Protagenic Therapeutics, Inc.new — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$5.53M -10.5% |
-$5.00M -40.6% |
-$3.56M +21.4% |
-$4.52M -77.5% |
-$2.55M -45.6% |
-$1.75M +31.5% |
| Diluted EPS | -$1.13 +1.7% |
-$1.15 -40.2% |
-$0.82 | — | — | — |
| Total Assets | $1.96M -54.8% |
$4.32M -46.2% |
$8.04M -27.3% |
$11.06M +1157.9% |
$879.2K +4.4% |
$842.3K +20.9% |
| Cash and Equivalents | — | — | — | — | $671.1K -16.0% |
$798.6K +120.3% |
| Stockholders Equity | $1.01M -72.4% |
$3.67M -47.0% |
$6.92M -30.4% |
$9.94M +964.7% |
-$1.15M -81.2% |
-$634.4K -200.8% |
| R&D Expense | $3.84M +25.5% |
$3.06M +92.8% |
$1.59M +39.8% |
$1.14M +62.4% |
$699.8K -13.4% |
$807.9K -8.3% |
| Operating Income | -$5.70M -25.9% |
-$4.53M -27.2% |
-$3.56M +14.1% |
-$4.14M -62.3% |
-$2.55M -22.3% |
-$2.09M +9.9% |
| Shares Outstanding | 7.24M +63.3% |
4.44M +2.6% |
4.32M +0.4% |
4.30M -58.5% |
10.36M +1.0% |
10.26M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $0.00 | — | — |
| Net Income | December 31, 2025 | $2.21M | +360.0% | +354.3% |
| Diluted EPS | December 31, 2025 | $1.14 | +812.5% | +342.6% |
| Total Assets | December 31, 2025 | $4.43M | +126.5% | -11.4% |
| Cash and Equivalents | March 31, 2021 | $191.7K | -74.6% | -71.4% |
| Stockholders Equity | December 31, 2025 | -$2.39M | +27.9% | +49.1% |
| R&D Expense | December 31, 2025 | $153.8K | +14.3% | -43.7% |
| Operating Income | December 31, 2025 | -$925.1K | -130.5% | +16.9% |
| Shares Outstanding | December 31, 2025 | 1.93M | +274.1% | +0.0% |
- Protagenic Therapeutics, Inc.new reported Total Revenue of $0.00 for fiscal year 2016.
- Protagenic Therapeutics, Inc.new reported Net Income of -$5.53 million for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed a decrease of -10.5% in Net Income compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Diluted EPS of $1.13 per share (loss) for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed an increase of +1.7% in Diluted EPS compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Total Assets of $1.96 million for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed a decrease of -54.8% in Total Assets compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Cash and Equivalents of $671.1 thousand for fiscal year 2020.
- Protagenic Therapeutics, Inc.new showed a decrease of -16.0% in Cash and Equivalents compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Stockholders Equity of $1.01 million for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed a decrease of -72.4% in Stockholders Equity compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported R&D Expense of $3.84 million for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Operating Income of -$5.70 million for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed a decrease of -25.9% in Operating Income compared to the prior fiscal year.
- Protagenic Therapeutics, Inc.new reported Shares Outstanding of 7.24 million shares for fiscal year 2024.
- Protagenic Therapeutics, Inc.new showed an increase of +63.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: